BAX and acute myeloid leukemia: The functional genomics screen of the AML cell line model, MOLM13, has shown the inactivation of the TP53 and BAX genes as key elements of venetoclax resistance, explaining venetoclax insensitivity in samples from AML patients who have low expression of these two genes [124].